BR112022002418A2 - Formulações de prolipossoma de undecanoato de testosterona - Google Patents

Formulações de prolipossoma de undecanoato de testosterona

Info

Publication number
BR112022002418A2
BR112022002418A2 BR112022002418A BR112022002418A BR112022002418A2 BR 112022002418 A2 BR112022002418 A2 BR 112022002418A2 BR 112022002418 A BR112022002418 A BR 112022002418A BR 112022002418 A BR112022002418 A BR 112022002418A BR 112022002418 A2 BR112022002418 A2 BR 112022002418A2
Authority
BR
Brazil
Prior art keywords
weight
proliposome
testosterone undecanoate
ratio
formulations
Prior art date
Application number
BR112022002418A
Other languages
English (en)
Inventor
V Betageri Guru
Natarajan Venkatesan
K Swarnakar Nitin
Ramachandran Thirucote
Teresa Hong
Gowda Kadajji Veeran
Original Assignee
Tesorx Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesorx Pharma Llc filed Critical Tesorx Pharma Llc
Publication of BR112022002418A2 publication Critical patent/BR112022002418A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Abstract

formulações de prolipossoma de undecanoato de testosterona a presente invenção diz respeito a dispersões de pó de prolipossoma de undecanoato de testosterona (tu) e fosfolipídios, incluindo dispersões de tu e palmitoilfosfatidilcolina (dppc), em que a razão peso/peso (p/p) de tu:dppc na dispersão de pó de prolipossoma é de cerca de 1:2; ou tu e 1,2-dimiristoil-sn-glicero-3-fosfocolina (dmpc), em que a razão peso/peso (p/p) de tu:dmpc na dispersão de pó de prolipossoma é de cerca de 1:3; ou tu e uma relação 1-miristoil-2-palmitoil-sn-gliceo 3-fosfocolina (mppc), em que a razão peso/peso (p/p) de tu:mppc na dispersão de pó de prolipossoma é de cerca de 1:3.
BR112022002418A 2019-08-09 2020-08-10 Formulações de prolipossoma de undecanoato de testosterona BR112022002418A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962884919P 2019-08-09 2019-08-09
PCT/US2020/045607 WO2021030260A1 (en) 2019-08-09 2020-08-10 Proliposomal testosterone undecanoate formulations

Publications (1)

Publication Number Publication Date
BR112022002418A2 true BR112022002418A2 (pt) 2022-06-14

Family

ID=74569809

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002418A BR112022002418A2 (pt) 2019-08-09 2020-08-10 Formulações de prolipossoma de undecanoato de testosterona

Country Status (13)

Country Link
US (1) US20220265679A1 (pt)
EP (1) EP4009950A4 (pt)
JP (1) JP2022544197A (pt)
KR (1) KR20220054318A (pt)
CN (1) CN114667133A (pt)
AR (1) AR122300A1 (pt)
AU (1) AU2020329775A1 (pt)
BR (1) BR112022002418A2 (pt)
CA (1) CA3146515A1 (pt)
IL (1) IL290464A (pt)
MX (1) MX2022001417A (pt)
TW (1) TW202216162A (pt)
WO (1) WO2021030260A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US8658202B2 (en) * 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
KR20150032939A (ko) * 2012-05-09 2015-03-31 웨스턴 유니버시티 오브 헬스 사이언시스 프로리포좀 테스토스테론 제제
JP2019501199A (ja) * 2016-01-08 2019-01-17 ウエスタン ユニバーシティ オブ ヘルス サイエンシズ プロリポソームテストステロンウンデカノエート製剤

Also Published As

Publication number Publication date
CN114667133A (zh) 2022-06-24
MX2022001417A (es) 2022-06-08
KR20220054318A (ko) 2022-05-02
US20220265679A1 (en) 2022-08-25
EP4009950A4 (en) 2023-07-05
IL290464A (en) 2022-04-01
TW202216162A (zh) 2022-05-01
JP2022544197A (ja) 2022-10-17
CA3146515A1 (en) 2021-02-18
WO2021030260A1 (en) 2021-02-18
EP4009950A1 (en) 2022-06-15
AR122300A1 (es) 2022-08-31
AU2020329775A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
CL2018002703A1 (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). (divisional solicitud 201401291)
CR20170356A (es) Composiciones farmacéuticas para terapia combinada
BR112019000690A2 (pt) composição auto-emulsificante de alta concentração, forma de dosagem oral de alta resistência e método de tratamento de um sintoma, doença ou distúrbio responsivo ao canabinóide
BR112017003419A2 (pt) formulação de anticorpo anti-il-4r-alfa estável
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
BR112015014654A2 (pt) solubilizado de curcumina
BR112012010706A2 (pt) composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio
BR112018077021A2 (pt) terapias de combinação
BRPI0921482A8 (pt) Uso de uma construção de anticorpo de cadeia simples biespecífica cd19xcd3 no tratamento de leucemia linfoblástica aguda
BR112015029987A8 (pt) Beta-caseína a2 e a prevenção de inflamação do intestino
BR112013016516A2 (pt) uso de óleo encapsulado na preparação de massas
BR112015024636A2 (pt) amassadeira e método de amasso
BR112013005069A2 (pt) Uso de uma preparação para a fabricação de um produto para a prevenção ou o tratamento de ansiedade ou depressão
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112018068771A2 (pt) blendas de okara e um produto de pectina contendo fibra
BR112015009486A2 (pt) surfactante reconstituído, formulação farmacêutica, kit e uso de surfactante reconstituído
BR112022001413A2 (pt) Preparação de canabidiol, e, método para tratar uma modificação da doença em um paciente que sofre de síndrome de dravet
MX2020011323A (es) Composicion farmaceutica para liberacion controlada de treprostinil.
BR112022002418A2 (pt) Formulações de prolipossoma de undecanoato de testosterona
BR112018076553A2 (pt) composição de dois componentes.
BR112016010351A2 (pt) Composições em forma de pó, métodos de produção de uma composição em forma de pó, preparação farmacêutica, e artigo médico
BR112018068817A2 (pt) beta-caseínas e função cognitiva
BR112018069900A2 (pt) composição antimicrobiana, método de limpeza ou desinfecção de uma superfície e uso de um complexo fosfolipídico catiônico
AR118985A1 (es) Composición que comprende fibra y proteína
BR112018013804A2 (pt) entrega baseada em alimentos de agentes terapêuticos para tratamento de encefalopatia hepática